Picture loading failed.

Anti-TNFRSF10B therapeutic antibody (Pre-made Conatumumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Conatumumab (originally AMG-655) is a monoclonal antibody developed for the treatment of cancer. It is a fully human monoclonal agonist antibody directed against the extracellular domain of human TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) receptor 2 (TR-2, death receptor 5) with potential antineoplastic activity. Conatumumab mimics the activity of native TRAIL, binding to and activating TR-2, thereby activating caspase cascades and inducing tumor cell apoptosis. TR-2 is expressed by a variety of solid tumors and cancers of hematopoietic origin.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-117-1mg 1mg 3090
GMP-Bios-ab-117-10mg 10mg 21890
GMP-Bios-ab-117-100mg 100mg 148000
GMP-Bios-ab-117-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-TNFRSF10B therapeutic antibody (Pre-made Conatumumab biosimilar,Whole mAb)
INN Name Conatumumab
TargetTNFRSF10B
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2008
Year Recommended2009
CompaniesAmgen;Takeda
Conditions Approvedna
Conditions ActiveSolid tumours
Conditions DiscontinuedColorectal cancer;Lymphoma;Non-small cell lung cancer;Pancreatic cancer;Sarcoma
Development TechAbgenix XenoMouse